DR. YEUNG: I would like to highlight a point that probably is relevant for this community in Southeast Asia where self-medication is common, making it difficult to predict what the breastfeeding infant will be exposed to. For that reason, doing an additional measurement the serum binding capacity, in our community might be important. I gave the first few slides in my late afternoon talk yesterday, while many of you were half asleep, but if you still remember what I talked about, mainly we could actually see the amount of displaced bilirubin with our new system. I'm not a salesman, neither am I a member of firms like Natus, but my collaborator for that equipment from the Department of Chemistry at my university reassured me that if he got the funding, he could easily assemble an automated equipment to do the tests as I have shown in my first couple of slides yesterday, which I actually changed with permission from the organizer. He could actually do it, it's an automated thing. And the total volume of serum required to get four points in that particular curve to get your binding capacity is only about 0.5 mls of serum. And again, the total time needed is less than 15 minutes. So I think with money and support, we probably can come up with that thing not too far from now. DR. BRATLID: Wouldn't measurements of unbound bilirubin give the same information? DR. YEUNG: I don't think so. As I mentioned earlier, I believe the law of mass action does not apply in the case of severe hyperbilirubinemia. By the time severe hyperbilirubinemia is present, unbound bilirubin precipitates out as soon as it's generated, because it's not soluble in the circulating blood. Thus, the actual amount of bilirubin that is measured at any time point in a child with severe hyperbilirubinemia does not reflect how much unbound bilirubin had been generated. That's why I thought that measuring the binding capacity makes slightly better sense. Even though the serum albumin level doesn't change in the first 5 days of life, the blinding capacity on day 1 is much less than it is on day 5. Some of these may be explained by pH or fatty acid, but I think we also need to consider what the mother might be using, such as herbs, aspirin, and so forth. An important educational goal for mothers, even in North America, is to teach them not to self-medicate with these substances.
DR. HANSEN: Dr. Bratlid, please comment on the advisability of changing established guidelines for determining kernicterus.
DR. BRATLID: Perhaps when these changes are contemplated, they should be done as part of a randomized controlled study to determine whether the new guidelines produce as reliable results as the old guidelines. You can't make changes based on ''feelings''; you have to study the effect of the changes for the change to be positive.
DR. CHOW KIN: Dr. Fok, based on your study, the effect of the Chinese herbal medicine is not as good as phenobarbital; before 1974, phototherapy was not available in Hong Kong. Since Chinese herbal medicine is not as good as phenobarbital, it has no place for treatment of hyperbilirubinemia. Parents should be told this.
DR. FOK: There has been no clinical trial to determine whether it's effective so we can't be sure. Perhaps herbs can improve your chi, which is very important.
DR. McDONAGH: It's not enough to show that these things induce conjugation. You have to show that these things, including phenobarbital, induce the specific isozyme that conjugates bilirubin. Many of the older studies looked at the effects and the inducers, but didn't make that distinction.
With respect to the studies from Shanghai and Beijing, it is not enough to show that something lowers serum bilirubin because sulfonamides will do that quickly.
DR. YAFFE: I want to encourage all of you, whether or not you are a US citizen, to apply for research funding from the National Institutes of Health to study the problem of bilirubin. Many institutes, in addition to the Child Health Institute, are interested in the problem of bilirubin. The National Institute of Child Health and Human Development (NICHD) has had a long-standing interest in neonatal hyperbilirubinemia. For nearly 10 years, we have been undertaking a series of studies, first in Greece with Timos Valaes, which we helped design and were conducted under contract mechanism. These studies were dose-and time-ranging to prevent hyperbilirubinemia in the newborn. The studies led to the randomized control trial by Jorge Martinez in Buenos Aires, which I now describe.
The rationale for this trial comes from the inhibition of heme oxygenase with tin mesoporphyrin. The study involved full-term infants with high plasma bilirubin levels (15 to 18 mg/dl) at approximately 48 to 96 hours of age. Infants were randomized to either a control group that received no therapy and a group that
received one dose of tin mesoporphyrin, 6 mol/kg. All infants who achieved a level of plasma bilirubin of 19.5 mg/dl were exposed to phototherapy. None of the treated group and 22% of the control group required supplemental phototherapy. Based on limited followup data, there have been no adverse effects in the treated group. All of these studies have been rescue studies; that is, the infants achieved a certain level of bilirubin and then went into phototherapy or received tin mesoporphyrin. We would like to initiate preventive studies based on Dr. Bhutani's nomogram. Infants who exceed the 75th percentile in the first 24 to 48 hours would be entered into either a treatment (mesoporphyrin) or control group. It is our long-term hope that those infants at risk defined by the nomogram receive tin mesoporphyrin on the day of birth or shortly thereafter before they go home from the hospital. This is a complicated procedure because of bureaucratic and administrative constraints both in the governmental and private sectors. The FDA will approve this drug for marketing in the United States provided there is sufficient data, and the NICHD is willing to support the effort. It's the company itself that is stalling progress.
DR. MAISELS: Why is there no study in the United States of this drug?
DR. YAFFE: One of the reasons for doing the studies in Greece and Argentina is that long-term follow-up is easier.
DR. GARTNER: Tin mesoporphyrin blocks synthesis of bilirubin and carbon monoxide as a neurotransmitter in the central nervous system. At a Rockefeller meeting, there was concern that such blocking can cause damage in the brain along with major changes in neurodevelopment, which in fact might not manifest for a long time. That's been one of the major theoretical concerns.
DR. YAFFE: What are we going to look for, and when are we going to look for it? As the Israeli study showed, there are deficiencies that occur from exposure to bilirubin. Carbon monoxide is an important signal in the brain, and its conceivable that it affects it. DR. STEVENSON: The metalloporphyrins are a valuable group with respect to their properties and with respect to this particular compound that the Rockefeller group has used in their work. There is little that distributes into the brain. There is some differential distribution that may avoid some of these kinds of problems. We also proposed a randomized control trial within the NICHD Neonatal Research Network, which would have looked at not only efficacy, which was fairly well established, but also at toxicity. But no study was approved, and there have been no studies in the United States.
DR. DENNERY: Dr. Maisels, you mentioned the use of intensive phototherapy as an alternative to exchange transfusion, and you described a rate of decrease of bilirubin of approximately 0.5 mg/dl per hour. In the extreme cases of high bilirubin, is that really sufficient, and are we sure that we are substituting the right therapy? DR. MAISELS: It depends on the cause of the hyperbilirubinemia, the amount of the bilirubin level, and the goals of treatment. No one is suggesting substituting phototherapy and for a bilirubin level of 30 mg/dl. In other words, if an infant receives phototherapy and, while the blood is being cross-matched, the level declines to 25 mg/dl, then one might decide to continue with phototherapy. The overwhelming majority of infants today, if treated promptly with phototherapy at bilirubin levels of 20, 25, or 27 mg/dl, will respond quite rapidly and effectively. There are no data comparing a group of infants who had phototherapy with a group who received exchange transfusions at those levels. On the other hand, almost every infant in Dr. Johnson's study who developed kernicterus had an exchange transfusion. The overwhelming majority of infants in the past who developed kernicterus also had exchange transfusions. So it's impossible to determine whether the actual active exchange transfusion can shift bilirubin in and out of the central nervous system at the time the exchange is being done. It is true, however, that exchange transfusion is the most rapid way to lower the bilirubin level. At what point does exchange transfusion become mandatory and phototherapy eliminated as an option? That question is impossible to answer because phototherapy is always used first. Practically speaking, you can't achieve an exchange transfusion until 2 to 3 hours after the child is first seen. The problem is to decide when phototherapy is not sufficient and exchange transfusion is necessary.
DR. BRATLID: It's also important to consider that as soon as phototherapy is initiated, photoisomers are produced, which are nontoxic and represent a part of the bilirubin that is measured. So even if the total bilirubin levels don't decline, some of the bilirubin is nontoxic. That percentage has been estimated at approximately 10% to 12% of the total bilirubin level.
DR. BHUTANI: Before we go on to the issues and discuss the risks of exchange versus the risk of kernicterus, I wanted to get a sense from panel members on the incidence of kernicterus in Scandinavia and Hong Kong. What is an acceptable rate of kernicterus in your countries? DR. BRATLID: Until recently, kernicterus was not seen in Norway as long as the standard diagnostic criteria were used. I personally have seen only one case. That was in a premature infant, with a birth weight of approximately 1700 to 1800 g, who was not recognized as jaundiced. Our criteria were not at fault; rather, the infant was born on a Friday and nobody realized he was jaundiced until Monday and had bilirubin levels of 450 mg/dl. Except for that case, we had no cases of kernicterus. Then we had two cases at a local hospital in Oslo. One was a black infant, and we have limited experience observing or treating blacks in Norway. So the acceptable level of kernicterus would be zero. It shouldn't occur in our population.
DR. FOK: We haven't seen kernicterus in Hong Kong for a long time. We have used the same guideline for exchange criterion -bilirubin level of 20 mg/dl -for the last 25 years. Based on Dr. Maisel's recommendation, we have moved toward a level of 25 mg/dl; it's a kinder, gentler approach to jaundiced infants. Over the last 16 years in my hospital, with an annual delivery of 6000 to 8000 infants, we have seen four cases of kernicterus, all in G6PD-deficient infants. Three were born just before a long holiday weekend.
DR. EBBESEN:
Dr. Bratlid, do we need to look more at complications of exchange transfusion? Previously, you had experience with exchange transfusions and very few complications. Today, we have very few exchange transfusions, and they are more likely to be associated with complications.
DR. BRATLID: Perhaps, but in Norway, these patients are centralized to four or five neonatal centers that do exchange transfusion, and our experience in that field is still sufficient.
DR. MAISELS: There was an implication that the changes in the academy guidelines for the management of jaundice were not based on evidence, which is not true. They were based on an extensive review of the existing literature with regard to the relationship between bilirubin levels and brain damage.
In addition, there is the issue of potential harm of the treatment. I'm aware of at least four cases of children who have developed brain damage after exchange transfusions. Children have experienced cardiac arrest; others have developed AIDS. I'm not offering these case reports as evidence to change management, but we must remember that the treatment itself carries a risk. The idea of changing the levels was based on our best evaluation of exchange transfusion at the levels that were currently being recommended.
The recommendation for phototherapy in the current academy guidelines is to consider it at a bilirubin level of 17 mg/dl and use it at 20 mg/dl in a full-term healthy infant, not one with known G6PD deficiency or Rh or ABO disease. If these guidelines were followed, we wouldn't be seeing kernicterus in the United States.
Your strong objection to the guidelines was that it was based on the clinical assessment objectives, but this is the way jaundice has been assessed for hundreds of years. The fact that some physicians look at infants who appear very jaundiced and decide not to measure bilirubin levels is not the fault of the academy's guidelines. The fact that infants are discharged at 24 hours and then are not seen again until they are 5 days to 1 week old, at which time they have a bilirubin level of 35 or 40 mg/dl, is also not the fault of the guideline. The reality is that the overwhelming majority of cases of kernicterus occurred because the guidelines were not followed.
DR. STEVENSON: The guidelines are being reviewed, and we are trying to do an exhaustive review of the literature to ensure that we are not missing any new evidence. We may make new recommendations based not only on data, but also on how people behave. In addition, we now have better ways to understand whether hemolysis is present than simply doing a Coombs' test, for example.
DR. JOHNSON: Why was a serum bilirubin ever analyzed if the clinical assessment of jaundice is so good? All we are saying is that measuring a serum bilirubin is not an adequate measure, in itself, of jaundice. Our main concern is to have a procedure that provides a safety net, at several different layers of surveillance, that identifies an infant with jaundice. The visual assessment of jaundice is fraught with difficulties, and we need to monitor infants more closely so that we can recognize levels of bilirubin that can be treated by phototherapy, which is a very safe modality. In our registry, eight infants were readmitted to the hospital on days 2.5 to 3 with bilirubin levels that were already dangerously high, and those infants had not been recognized as being at risk. Another group came in on day 4, which would be a traditional time for seeing a infant again, but they were not recognized as being high risk and were sent home or told to return in 12 to 24 hours. We need to tighten those guidelines and help the doctor who is practicing by himself on weekends to diagnose these infants.
DR. MAISELS: I agree, but I want to point out that the current guidelines were published in 1994. The data you refer to about the difficulty of recognizing bilirubin levels come from a 1941 study, and the highest level in the 1941 study was 12 mg/dl. Obviously, a child who goes home at 24 hours with a bilirubin level of 10 mg/dl has a very high level, and it's difficult to tell the difference between that bilirubin level and a level of 5 mg/dl. When you send a child home on day 1 or 27 hours, it's quite easy to miss the jaundice. That's why it's essential to have an appropriate follow-up evaluation. But to blame the 1994 guidelines because they said the child should be treated when significant jaundice was present or a bilirubin level should be measured is unfair. That was the level of practice of the day.
DR. JOHNSON: But Dr. Maisel, have you never missed jaundice in a infant whose bilirubin was higher than 10 mg/dl? DR. MAISELS: I may well have done so. DR. JOHNSON: Maybe in a black infant? DR. MAISELS: I may have, but if I had seen the infant a day or two later, I would hope I would have detected it then.
DR. FANAROFF: I tend to agree with Dr. Stevenson, that although it's desirable to have a zero rate, it may be an unreasonable goal, particularly given the fact that we are not recognizing all the cases of bilirubin encephalopathy. Realistically, one could design a screening system with as fine a screen so as to catch the bulk at-risk infants. I don't think that you are ever going to achieve a rate of zero.
DR. GARTNER: I want to emphasize the issue of maximizing the effectiveness of phototherapy by feeding the infants. According to the NICHD phototherapy study, feeding these premature infants more than 90 cal/kg per day, whether orally or intravenously, was just as effective in reducing the bilirubin level as giving them phototherapy and less than 60 cal/kg per day. To maximize treatment, it would be reasonable to give phototherapy plus diet of 90 cal/kg per day. In practice, a 3-or 4-day-old infant is admitted to the hospital for phototherapy and is fed intravenously, which discourages the infant from eating and reduces caloric intake, which in turn reduces the effectiveness of the phototherapy.
DR. KAPLAN: I am concerned by Dr. Bratlid's suggestion that indication for therapy should possibly be based on electrophysiologic changes that are reversible. We know that the test is reversible, but is there perhaps some additional brain damage that is not reversible? What set me thinking about this is the sight of the Israeli recruits, not the sight of those with the low IQ, but the sight of those with the high IQ. Maybe their electrophysiologic tests have returned to normal but we've lopped off a few IQ points.
DR. BRATLID:
We are focusing too much on kernicterus. Are there other toxic effects of bilirubin that we should also consider when devising guidelines and treatment criteria? Do we know if the peak bilirubin level is more important than the area under the curve, which to some extent is a valid parameter for other drug toxicity?
DR. LARRY BAUSCH: Relative to the problem of combined jaundice in which we may have bilirubin levels of 8 mg/dl with direct or unbound fractions of 12 mg/dl, should any special consideration be given to those infants with respect to treatment?
DR. MAISELS: We don't have data to answer this question, but we all have anecdotal experience. My recommendation is to completely ignore the direct bilirubin level. In other words, if the level is high enough to warrant exchange transfusion, but if the direct level is elevated, under no circumstances should the direct level be subtracted from the total. We have seen too many infants who have developed kernicterus who have had relatively low indirect levels, but who had high levels when the direct levels were added. In fact, I saw one infant who had a total bilirubin level of 43 mg/dl, but a direct of level of 32 mg/dl, so the indirect level was only 11 mg/dl. This child had erythroblastosis, a classic magnetic resonance image of kernicterus, and classic kernicterus.
DR. STEVENSON:
We have seen what happens with elevated direct levels of bilirubin. The lipid profiles change rapidly and red cell membranes are affected. We have demonstrated this in rats and in the biliary atresia kids; a part of that syndrome where you end up with sort of a steady state is that they have a chronic hemolytic circumstance feeding the problem and the cholestatic problems don't resolve quickly. So the call that I get from some physicians that's even worse is, ''I'm doing my fourth exchange transfusion and the levels are still 25 and 18. What do I do?''. I don't know what to tell these physicians.
DR. HANSEN: Just a comment regarding Dr. Maisel's presentation on practical aspects of phototherapy. Although we are always eager to see new and more efficient equipment, many are in practices where this equipment is not available. A lot can be done with old phototherapy units. A few years ago, we made some small changes in our equipment, simply cleaning the filters, putting in new tubes, and so forth. Instead of using tin foil, we put a clean, sparkling white sheet in the crib and then hung a white sheet around the whole unit. I measured the photo energy before and after the changes. The total energy delivered doubled: The energy delivered to the infant's flank was increased by a factor of more than 10, and the average duration of phototherapy for a full-term healthy infant decreased to 17 hours. We achieved this improvement with no additional costs.
